Remyelination candidate misses phase 2
Continuem’s remyelinating agent PIPE‑307 failed to meet its primary endpoint in a phase 2 relapsing‑remitting MS trial, a setback that can shift regulator and sponsor focus toward cleaner safety packages and better enrichment strategies. (neurologylive.com).
Contineum Therapeutics told investors on Nov. 20, 2025 that its phase 2 VISTA trial of PIPE‑307 failed to hit its prespecified efficacy goals. (businesswire.com). PIPE‑307 is a small‑molecule oral drug that blocks the M1 muscarinic acetylcholine receptor, a target chosen because preclinical work suggested M1 modulation might nudge oligodendrocyte precursor cells to remyelinate damaged axons. (neurologylive.com). The VISTA study randomized about 168 patients with relapsing‑remitting multiple sclerosis to two doses of PIPE‑307 or placebo, treated them for roughly 26 weeks, and was double‑blind and placebo‑controlled. (clinicaltrials.gov). Contineum’s primary outcome was change in binocular 2.5% low‑contrast letter acuity (LCLA), a vision test sensitive to subtle losses or gains in optic‑nerve myelination that investigators often use as a clinical readout for remyelination. (clinicaltrials.gov) (journals.sagepub.com). Topline readouts showed no statistically significant difference between PIPE‑307 and placebo on that LCLA measure, and the company reported the trial did not meet its prespecified primary or secondary efficacy endpoints. (businesswire.com). Contineum said both doses of PIPE‑307 were acceptable from a tolerability standpoint and that no new safety signals emerged in VISTA. (businesswire.com). Failing an efficacy endpoint in a remyelination trial is not a simple "the drug doesn’t work" verdict; it can reflect choice of dose, patient population, endpoint sensitivity, or timing of assessment. (neurologylive.com) (neurologyopen.bmj.com). Low‑contrast letter acuity is widely adopted because it picks up visual dysfunction that standard high‑contrast charts miss, but it is a functional proxy for myelin repair rather than a direct biomarker of new myelin. (journals.sagepub.com) (academic.oup.com). For regulators and sponsors, a neutral efficacy readout combined with a clean safety profile steers the next decisions. (businesswire.com). The U.S. Food and Drug Administration already encourages use of enrichment strategies—selecting trial populations or biomarkers to amplify a treatment signal—and those play a clear role when a phase 2 fails on a broadly enrolled cohort. (fda.gov). Regulators and international bodies also provide frameworks for focused safety data collection and aggregate safety assessment, tools sponsors can lean on when pivoting after negative efficacy data. (ema.europa.eu) (link.springer.com). Industry press noted the VISTA topline will prompt partners and investors to reassess development plans and enrichment tactics; pipeline partners often pause or demand additional biomarker evidence after such readouts. (fiercebiotech.com) (clinicaltrialsarena.com). Contineum plans to dig into exploratory endpoints and present a full dataset at a medical meeting before publishing in a peer‑reviewed journal, a concrete next step that will supply the details regulators and safety teams need to judge whether a different design, biomarker, or dose could change the story. (businesswire.com).
